Metastatic Colorectal Cancer Market is Driven by Targeted Therapies
The metastatic colorectal cancer (mCRC) market encompasses a broad spectrum of treatment modalities designed to improve survival outcomes and quality of life for patients with advanced disease. Key products include monoclonal antibodies, tyrosine kinase inhibitors, immunotherapies, and personalized combination regimens that target specific genetic mutations such as KRAS, NRAS, and BRAF. These...
0 Reacties 0 aandelen 73 Views 0 voorbeeld